Loading
A phase 2 trial of Azacitidine in advanced solid tumours, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms is a phase 2 interventional study registered as NCT06858618 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 47 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2026-12-01. Interventions recorded: FCN-338 + Azacitidine and FCN-338 + erythromycin+ Ara-C.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/